Objective:To explore the expression levels of matrix metalloproteinase-2(MMP-2)and matrix metalloproteinase-9(MMP-9)in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluatio...Objective:To explore the expression levels of matrix metalloproteinase-2(MMP-2)and matrix metalloproteinase-9(MMP-9)in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods:ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor,and RIA was used to detect the expression level of CA125 in the serum in these patients.Results:The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor(t=8.08,10.39,p<.01),and the difference was of statistical significance.The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors,and the difference was statistically significant(t=2.75,2.75,p<.05).There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types,different histological grades,lymph node metastasis or not,different ascites volumes and different residual lesions(p>.05).The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0%and 88.0%,respectively,which were significantly higher than those of ascites cytological examinations(χ^(2)=4.61,12.74,p<.05),but in comparison with serum CA125,there was no statistically significant difference(p>.05).The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3%and 82.6%,respectively,which were significantly lower than those of ascites cytological examinations(χ^(2)=5.61,4.38,p<.05),but in comparison with serum CA125,there was no statistically significant difference(χ^(2)=1.64,2.68,p<.05).Conclusions:The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions,and they are related to the prognosis in patients with malignant ovarian tumors.展开更多
文摘Objective:To explore the expression levels of matrix metalloproteinase-2(MMP-2)and matrix metalloproteinase-9(MMP-9)in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods:ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor,and RIA was used to detect the expression level of CA125 in the serum in these patients.Results:The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor(t=8.08,10.39,p<.01),and the difference was of statistical significance.The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors,and the difference was statistically significant(t=2.75,2.75,p<.05).There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types,different histological grades,lymph node metastasis or not,different ascites volumes and different residual lesions(p>.05).The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0%and 88.0%,respectively,which were significantly higher than those of ascites cytological examinations(χ^(2)=4.61,12.74,p<.05),but in comparison with serum CA125,there was no statistically significant difference(p>.05).The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3%and 82.6%,respectively,which were significantly lower than those of ascites cytological examinations(χ^(2)=5.61,4.38,p<.05),but in comparison with serum CA125,there was no statistically significant difference(χ^(2)=1.64,2.68,p<.05).Conclusions:The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions,and they are related to the prognosis in patients with malignant ovarian tumors.
